NEWS

WIRES

OTHER

Oragenics, Inc. Presents Teddy's Pride Oral Care Probiotics At The 2011 Global Pet Expo

ProBiora3, the active ingredient in Teddy's Pride, was developed by Oragenics' Chief Scientific Officer, Dr. Jeffrey D. Hillman, D.M.D., Ph.D., during more than 25 years of research which began at the Harvard-affiliated Forsyth Institute in Boston and continued at the University of Florida. This technology has only recently become available to the general public in Teddy's Pride, along with a line of oral care probiotic products for the entire family. The ProBiora3 blend of beneficial bacteria contains three strains of probiotics that help maintain a healthy microbial balance in the mouth. ProBiora3 is made in the USA in an FDA-registered facility. All ProBiora3-containing products are 100% natural.

Teddy's Pride oral care probiotics are specifically formulated for cats and dogs of all sizes and ages. Teddy's Pride kills harmful, bad-breath causing bacteria and adds the beneficial bacteria that naturally thrive in the mouth. This innovative new oral care product naturally freshens pets' breath while gently and naturally whitening teeth.

According to the American Pet Product Association, the pet industry is one of the few that has consistently experienced strong growth for the past several years. Teddy's Pride is an innovative addition to the $47 billion dollar pet industry. It is a convenient, reliable and affordable oral care product for the 71.4 million US households that own a pet.

"The Global Pet Expo is a wonderful place to meet with fellow American Pet Products Association members and pet industry experts, " said Gerry David, Executive Vice President, Sales and Marketing for Oragenics. "Attracting thousands of pet professionals from all over the world, Global Pet Expo is an ideal place to exhibit this unique product for dogs and cats."

About Oragenics, Inc.

Oragenics is a biopharmaceutical company focused primarily on oral health products and novel antibiotics. Within oral health, Oragenics is developing its pharmaceutical product candidate, SMaRT Replacement Therapy, along with its consumer oral care products featuring ProBiora3. Within antibiotics, Oragenics is developing a pharmaceutical candidate, MU1140-S and intends to use its patented, novel organic DPOLT platform to create additional antibiotics for therapeutic use.

About Global Pet Expo

Global Pet Expo, the pet industry's largest annual trade show, is presented by the American Pet Products Association (APPA) and Pet Industry Distributors Association (PIDA). The 2010 Global Pet Expo drew nearly 5,000 pet product retail buyers from around the world. Global Pet Expo is open to independent retailers, distributors, mass-market buyers, and other qualified professionals. APPA is the leading not-for-profit trade association made up of over 1,000 pet product manufacturers, their representatives, importers and livestock suppliers. APPA's membership consists of a diverse group representing both large corporations and growing business enterprises worldwide.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to (i) the actual suitability of ProBiora3 for inclusion in other products, and (ii) our ability to successfully incorporate ProBiora3 into other products, as well as those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

MEDIA CONTACT: For more information about the company, visit www.oragenics.com or contact Robert Koski at (813) 286-7900.

Oragenics, Inc.
Robert Koski, 813-286-7900
www.oragenics.com